Discontinuation/Interruption of Warfarin Therapy in Patients with Non-Valvular Atrial Fibrillation.

Wang, J; Qiao, Y; Spivey, C A; Liu, X; Phatak, H; Mardekian, J; Claflin, A B; Kachroo, S; Abdulsatter, Y; Parker, R B

Wang, J; Qiao, Y; Spivey, C A; Liu, X; Phatak, H; Mardekian, J; Claflin, A B; Kachroo, S; Abdulsatter, Y; Parker, R B.

Afiliação

Wang J; The University of Tennessee College of Pharmacy, Memphis, TN, USA.
Qiao Y; The University of Tennessee College of Pharmacy, Memphis, TN, USA.
Spivey CA; The University of Tennessee College of Pharmacy, Memphis, TN, USA.
Liu X; University of Tennessee, College of Pharmacy, New York, NY, USA.
Phatak H; Bristol-Myers Squibb Company, Princeton, NJ, USA.
Mardekian J; Pfizer, Inc., New York, NY, USA.
Claflin AB; Pfizer, Inc., New York, NY, USA.
Kachroo S; Bristol-Myers Squibb Company, Princeton, NJ, USA.
Abdulsatter Y; Pfizer, Inc., New York, NY, USA.
Parker RB; The University of Tennessee College of Pharmacy, Memphis, TN, USA.

Value Health ; 17(7): A763, 2014 Nov.

Article em En | MEDLINE | ID: mdl-27202796

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2014 Tipo de documento: Article